NCT01690624View on ClinicalTrials.gov

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to Relapse

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 13, 2012

Primary Completion Date

May 21, 2018

Study Completion Date

May 21, 2018

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

BI 836858

Monotherapy with BI 836858 administered as intravenous infusion

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

21287

Johns Hopkins Hospital, Baltimore

43210

The Ohio State University Wexner Medical Center, Columbus

60611

Northwestern University, Chicago

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY